GO:0031692 alpha-1B adrenergic receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031692 alpha-1B adrenergic receptor binding is a molecular function defined as binding to an alpha-1B adrenergic receptor (ADRA1B).
• The alpha-1B adrenergic receptor is a G protein-coupled receptor whose structure and ligand recognition determinants have been resolved by crystallography.
• Alpha-1 adrenoceptor subtypes, including alpha-1B, mediate diverse physiological responses and are drug targets in cardiovascular and urological disease.
• Ligand binding to alpha-1B is studied using NMR-optimized receptor constructs and chromatographic thermodynamic assays.
• Off-target binding of beta-3 agonists such as mirabegron to alpha-1A receptors illustrates the pharmacological importance of subtype-selective ligand recognition.
• Chemokine receptor signaling, including CCR1, can modulate alpha-1B adrenoceptor function, linking this binding function to inflammatory and cardiovascular biology.
Description
GO:0031692 alpha-1B adrenergic receptor binding is a molecular function term that describes the binding of a ligand or protein to the alpha-1B adrenergic receptor, a G protein-coupled receptor encoded by the ADRA1B gene. This binding event is the first step in receptor activation and is central to understanding how endogenous catecholamines and synthetic adrenergic drugs initiate signaling. The alpha-1B adrenergic receptor is one of three alpha-1 adrenoceptor subtypes (alpha-1A, alpha-1B, alpha-1D) that mediate the actions of norepinephrine and epinephrine in the cardiovascular, urogenital, and central nervous systems. Researchers study this binding function to dissect subtype-selective pharmacology, to design drugs with fewer off-target effects, and to understand how receptor structure determines ligand recognition. Recent structural and biophysical work has optimized the alpha-1B receptor for solution NMR studies and provided crystal structures that reveal molecular determinants of selective ligand recognition. In parallel, functional studies show that alpha-1B adrenoceptor signaling can be modulated by other receptors, such as chemokine receptor CCR1, expanding the biological context of this binding function. Because alpha-1B adrenergic receptor binding underlies both physiological regulation and pharmacological intervention, it is a key molecular function for researchers in receptor biology, drug discovery, and cardiovascular science.
alpha-1B adrenergic receptor binding At A Glance
| GO ID | GO:0031692 |
|---|---|
| GO term | alpha-1B adrenergic receptor binding |
| Ontology | molecular_function |
| Synonym | alpha-1B adrenergic receptor ligand |
| Definition | Binding to an alpha-1B adrenergic receptor. |
| Major function | Ligand recognition and initiation of alpha-1B adrenoceptor-mediated signaling |
| Receptor gene | ADRA1B encodes the alpha-1B adrenergic receptor |
| Subtype family | Alpha-1 adrenoceptor subtype, one of alpha-1A, alpha-1B, alpha-1D |
| Research relevance | Target for cardiovascular, urological, and anti-inflammatory drug discovery |
What Is GO:0031692?
In simple terms, GO:0031692 alpha-1B adrenergic receptor binding means a molecule physically attaches to the alpha-1B adrenergic receptor. The QuickGO definition states that this molecular function is the binding to an alpha-1B adrenergic receptor. The term is used to annotate gene products that interact with the alpha-1B adrenergic receptor (ADRA1B), including endogenous catecholamines, synthetic adrenergic ligands, and proteins that modulate receptor activity. This binding function is distinct from binding to other adrenoceptor subtypes, such as alpha-1A or alpha-1D, and is therefore important for subtype-selective pharmacology.
Why Is alpha-1B adrenergic receptor binding Important in Cell Biology?
GO:0031692 alpha-1B adrenergic receptor binding is important because it defines the molecular recognition step that governs alpha-1B adrenoceptor activation, a process implicated in blood pressure regulation, smooth muscle contraction, and neurotransmitter release. Structural studies of the alpha-1B receptor have revealed how ligands selectively engage this subtype, providing a template for rational drug design. Off-target binding of drugs such as mirabegron to alpha-1 receptors highlights the clinical need to understand subtype selectivity at the binding level. Moreover, crosstalk between chemokine receptors and alpha-1B adrenoceptors suggests that this binding function participates in inflammatory and cardiovascular signaling networks. Therefore, researchers studying receptor pharmacology, cardiovascular physiology, and drug safety rely on this GO term to annotate and interpret ligand-receptor interactions.
• Defines the primary molecular event for alpha-1B adrenoceptor activation by catecholamines and synthetic ligands.
• Enables subtype-selective drug design to avoid off-target effects such as beta-3 agonist binding to alpha-1A receptors.
• Provides a structural framework for understanding ligand recognition determinants in adrenergic receptors.
• Supports biophysical studies using NMR-optimized receptor constructs to probe ligand binding.
• Facilitates thermodynamic and extra-thermodynamic characterization of ligand binding by chromatographic methods.
• Links to cardiovascular physiology through alpha-1B adrenoceptor-mediated signaling.
• Connects to inflammatory signaling via chemokine receptor modulation of alpha-1B adrenoceptor function.
• Aids in interpreting pharmacological data for drugs with alpha-1 adrenergic receptor blocker activity.
• Provides a basis for annotating gene products that interact with ADRA1B in functional genomics.
• Helps researchers distinguish alpha-1B binding from other adrenoceptor subtype interactions in drug discovery.
Molecular Mechanism of alpha-1B adrenergic receptor binding
Ligand recognition and binding pocket
In simple terms: The receptor has a pocket where ligands fit, and the shape of this pocket determines which molecules can bind.
The alpha-1B adrenergic receptor binds ligands through a binding pocket formed by transmembrane helices, and crystal structures have revealed molecular determinants of selective ligand recognition. This binding pocket accommodates catecholamines and synthetic adrenergic ligands, and structural comparisons with other alpha-1 subtypes explain differences in subtype selectivity. The receptor can be optimized for solution NMR studies to probe these interactions in a membrane-like environment.
Subtype selectivity and off-target binding
In simple terms: Different alpha-1 receptor subtypes can bind the same drug, which can cause unintended effects.
Alpha-1 adrenoceptor subtypes share structural similarity, but ligand binding can differ. For example, the beta-3 adrenergic agonist mirabegron shows off-target binding to alpha-1A adrenergic receptors, illustrating the importance of subtype-selective interactions. Structural studies of alpha-1A receptor activation and nanobody recognition further inform how subtype-specific binding occurs. These findings help researchers design ligands that preferentially bind alpha-1B over other subtypes.
Thermodynamic and biophysical characterization
In simple terms: Scientists measure how strongly and how differently ligands stick to the receptor using physical methods.
Binding of ligands to alpha-1A adrenergic receptor has been studied by site-selective covalent immobilization and chromatographic methods to determine thermodynamic and extra-thermodynamic parameters. Similar approaches can be applied to alpha-1B to quantify binding affinity and selectivity. NMR studies of optimized alpha-1B receptor constructs provide residue-level information about ligand-receptor interactions.
Receptor activation and signaling modulation
In simple terms: Once a ligand binds, the receptor can change shape and trigger signals inside the cell, and other receptors can influence this process.
Ligand binding to alpha-1B adrenergic receptor initiates conformational changes that lead to G protein activation and downstream signaling. Activation of chemokine (C-C motif) receptor 1 (CCR1) can modulate alpha-1B adrenoceptor and arginine vasopressin receptor 1A signaling and function, indicating that binding events are integrated into broader signaling networks. Chemokine receptor antagonists with alpha-1-adrenergic receptor blocker activity further demonstrate the pharmacological overlap between these systems.
Pharmacological relevance of alpha-1B binding
In simple terms: Understanding how drugs bind to alpha-1B helps predict their effects and side effects.
Alpha-1 adrenoceptor subtypes are targets for drugs used in cardiovascular and urological conditions, and binding selectivity determines therapeutic and adverse effects. The crystal structure of alpha-1B provides a basis for structure-based drug design. Off-target binding studies, such as those with mirabegron, highlight the need to evaluate ligand interactions across adrenoceptor subtypes. Together, these data make GO:0031692 a key annotation for pharmacological research.
Key Genes Involved in GO:0031692 alpha-1B adrenergic receptor binding
The following genes and proteins are directly or functionally linked to alpha-1B adrenergic receptor binding and its signaling context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRA1B | Encodes the alpha-1B adrenergic receptor, the direct binding target of GO:0031692 | Structural and pharmacological studies of ligand recognition |
| ADRA1A | Encodes alpha-1A adrenergic receptor, a related subtype with distinct binding properties | Comparative binding and off-target studies |
| ADRA1D | Encodes alpha-1D adrenergic receptor, another alpha-1 subtype | Subtype selectivity research |
| ADRB3 | Encodes beta-3 adrenergic receptor, target of mirabegron which shows off-target alpha-1A binding | Off-target binding studies |
| CCR1 | Chemokine receptor that modulates alpha-1B adrenoceptor signaling | Receptor crosstalk and cardiovascular function |
| AVPR1A | Arginine vasopressin receptor 1A, modulated together with alpha-1B by CCR1 | Signaling integration studies |
| GNAQ | G protein alpha q subunit, canonical downstream effector of alpha-1B | Signal transduction research |
| GNA11 | G protein alpha 11 subunit, coupled to alpha-1 adrenoceptors | Receptor signaling studies |
| GNAS | G protein alpha s subunit, potential crosstalk in adrenergic signaling | GPCR signaling context |
| ARRB1 | Beta-arrestin 1, involved in GPCR desensitization | Receptor regulation studies |
| ARRB2 | Beta-arrestin 2, involved in GPCR internalization | Receptor regulation studies |
| PRKCA | Protein kinase C alpha, downstream of alpha-1 adrenoceptor activation | Signaling pathway analysis |
| PLCB1 | Phospholipase C beta 1, effector of Gq-coupled alpha-1B | Second messenger studies |
| SLC6A2 | Norepinephrine transporter, regulates catecholamine availability | Neurotransmission and binding studies |
| COMT | Catechol-O-methyltransferase, metabolizes catecholamines | Ligand availability research |
| MAOA | Monoamine oxidase A, catecholamine metabolism | Neuropharmacology |
| MAOB | Monoamine oxidase B, catecholamine metabolism | Neuropharmacology |
| DBH | Dopamine beta-hydroxylase, synthesizes norepinephrine | Catecholamine synthesis research |
How Is alpha-1B adrenergic receptor binding Regulated?
The binding function of alpha-1B adrenergic receptor is regulated at multiple levels. Receptor availability and ligand access are influenced by catecholamine synthesis, storage, and reuptake, which involve enzymes and transporters such as DBH, SLC6A2, COMT, MAOA, and MAOB. At the receptor level, GPCR desensitization and internalization mediated by beta-arrestins (ARRB1, ARRB2) and phosphorylation by kinases such as PRKCA can modulate the consequences of ligand binding. Additionally, crosstalk from other receptors, such as CCR1, can modulate alpha-1B adrenoceptor signaling and function, indicating heterologous regulation. These regulatory mechanisms ensure that alpha-1B adrenergic receptor binding is context-dependent and integrated with other signaling pathways.
alpha-1B adrenergic receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRA1B | Hypertension and cardiovascular regulation | ADRA1B knockout or point-mutation cell models for ligand binding assays |
| ADRA1A | Off-target drug effects in overactive bladder treatment | ADRA1A knock-in or overexpression cells for mirabegron binding studies |
| CCR1 | Inflammatory signaling and cardiovascular function | CCR1 knockout cells to study modulation of alpha-1B signaling |
| ADRB3 | Metabolic and urological disorders | ADRB3 overexpression models for off-target binding profiling |
| AVPR1A | Cardiovascular and fluid balance disorders | AVPR1A knockout models for crosstalk studies with alpha-1B |
Cardiovascular disease and hypertension
Alpha-1 adrenoceptor subtypes, including alpha-1B, mediate vasoconstriction and are targets for antihypertensive drugs. Binding of ligands to alpha-1B can influence blood pressure regulation, and chemokine receptor CCR1 modulation of alpha-1B adrenoceptor signaling has been linked to cardiovascular function. Drugs with alpha-1-adrenergic receptor blocker activity are used in cardiovascular and urological conditions, underscoring the clinical relevance of this binding function.
Urological disorders and off-target drug effects
Alpha-1 adrenoceptors are targets for treating benign prostatic hyperplasia and lower urinary tract symptoms. The beta-3 agonist mirabegron, used for overactive bladder, shows off-target binding to alpha-1A adrenergic receptors, highlighting the need to understand subtype-selective binding to avoid side effects. Structural knowledge of alpha-1B ligand recognition can guide development of more selective drugs.
Inflammatory and immune signaling
Chemokine receptors such as CCR1 can modulate alpha-1B adrenoceptor signaling, linking alpha-1B binding to inflammatory pathways. Chemokine receptor antagonists with alpha-1-adrenergic receptor blocker activity further demonstrate the intersection between chemokine and adrenergic systems. This crosstalk suggests that alpha-1B binding may be relevant in inflammatory diseases where chemokine signaling is dysregulated.
From alpha-1B adrenergic receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ADRA1B mediate specific ligand binding? | ADRA1B knockout cell line |
| How does a point mutation affect ligand selectivity? | Point-mutation knock-in of ADRA1B |
| Can a tagged receptor be used for binding assays? | Tagged knock-in of ADRA1B |
| What is the effect of receptor overexpression on signaling? | ADRA1B overexpression cell model |
| How does CCR1 modulate alpha-1B function? | CCR1 knockout or overexpression with ADRA1B readouts |
| Can subtype-selective ligands be identified? | Panel of ADRA1A, ADRA1B, ADRA1D knockout/knock-in cells |
How to Study the alpha-1B adrenergic receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Three-dimensional structure of receptor-ligand complex | Determining binding pocket and selectivity determinants |
| Solution NMR | Ligand-receptor interactions in solution | Probing conformational changes upon binding |
| Chromatographic binding assay | Thermodynamic and extra-thermodynamic binding parameters | Comparing ligand affinities |
| Radioligand binding assay | Binding affinity and competition | Pharmacological profiling of alpha-1B ligands |
| Off-target binding panel | Selectivity across adrenoceptor subtypes | Safety assessment of drugs like mirabegron |
| Functional calcium flux assay | Gq-mediated signaling after receptor activation | Measuring agonist efficacy at alpha-1B |
| Co-immunoprecipitation | Protein-protein interactions with alpha-1B | Identifying receptor complexes |
| Site-directed mutagenesis | Effect of specific residues on binding | Mapping ligand contact sites |
Structural biology (crystallography and NMR)
Crystal structures of the alpha-1B adrenergic receptor have revealed molecular determinants of selective ligand recognition. Solution NMR studies using optimized receptor constructs allow probing of ligand-receptor interactions in solution. These methods provide atomic-level insights into the binding function GO:0031692.
Biophysical and chromatographic binding assays
Site-selective covalent immobilization of alpha-1A adrenergic receptor combined with chromatographic methods enables thermodynamic and extra-thermodynamic characterization of ligand binding. Similar approaches can be adapted for alpha-1B to measure binding affinity and selectivity.
Pharmacological profiling and off-target screening
Ligand-receptor interaction studies, such as those examining mirabegron binding to alpha-1A receptors, help identify off-target effects. Chemokine receptor antagonists with alpha-1-adrenergic receptor blocker activity illustrate the importance of profiling compound selectivity across receptor families.
Functional signaling assays
Downstream signaling assays measuring G protein activation, second messengers, or receptor crosstalk can assess the functional consequences of alpha-1B binding. CCR1 modulation of alpha-1B adrenoceptor signaling provides a model for studying heterologous regulation.
How CRISPR Can Be Used to Study GO:0031692 alpha-1B adrenergic receptor binding
Knockout
CRISPR knockout of ADRA1B can eliminate alpha-1B adrenergic receptor binding, providing a clean background to study ligand specificity and downstream signaling. Knockout cells are useful for validating whether observed binding is indeed mediated by ADRA1B and for comparing with other alpha-1 subtypes.
Point Mutation
Point mutations introduced by CRISPR can alter specific residues in the ADRA1B binding pocket to test their role in ligand recognition, as suggested by structural studies. Such models help dissect molecular determinants of selective ligand binding and off-target interactions.
Knock-in
Knock-in of tagged or reporter versions of ADRA1B allows tracking of receptor localization and binding in live cells. Tagged knock-in models can facilitate biophysical assays such as NMR or fluorescence-based binding studies.
Overexpression
Overexpression of ADRA1B in cell lines can amplify binding signals for pharmacological screening and structural studies. Overexpression models are also useful for studying crosstalk with other receptors such as CCR1.
How EDITGENE Supports alpha-1B adrenergic receptor binding Research
Researchers studying alpha-1B adrenergic receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor signaling, or disease-associated phenotypes. CRISPR-based cell models provide a precise way to manipulate ADRA1B and related genes, enabling functional validation of binding mechanisms and drug targets.
Contact EDITGENE today to design your custom CRISPR model for alpha-1B adrenergic receptor binding research.
Frequently Asked Questions About alpha-1B adrenergic receptor binding
What is GO:0031692 alpha-1B adrenergic receptor binding?
GO:0031692 is a molecular function term defined as binding to an alpha-1B adrenergic receptor, a G protein-coupled receptor encoded by ADRA1B.
What genes are involved in alpha-1B adrenergic receptor binding?
The primary gene is ADRA1B, which encodes the alpha-1B adrenergic receptor; related genes include ADRA1A, ADRA1D, and signaling partners such as GNAQ and PLCB1.
What is the function of the alpha-1B adrenergic receptor?
It mediates responses to catecholamines such as norepinephrine and epinephrine, leading to Gq-mediated signaling and physiological effects in cardiovascular and other systems.
How is alpha-1B adrenergic receptor binding studied?
It is studied using structural biology (crystallography, NMR), biophysical binding assays, pharmacological profiling, and functional signaling assays.
Why is subtype selectivity important for alpha-1 adrenergic receptors?
Subtype selectivity determines therapeutic effects and off-target side effects; for example, mirabegron shows off-target binding to alpha-1A receptors.
What diseases are linked to alpha-1B adrenergic receptor binding?
It is linked to cardiovascular regulation, hypertension, urological disorders, and inflammatory signaling through crosstalk with chemokine receptors.
Can CRISPR be used to study alpha-1B adrenergic receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect binding mechanisms and signaling.
What is the structure of the alpha-1B adrenergic receptor?
Crystal structures have revealed the receptor's binding pocket and molecular determinants of selective ligand recognition.
How does CCR1 modulate alpha-1B adrenoceptor signaling?
Activation of CCR1 can modulate alpha-1B adrenoceptor and arginine vasopressin receptor 1A signaling and function, indicating receptor crosstalk.
What are the synonyms for GO:0031692?
The synonym is alpha-1B adrenergic receptor ligand.
Conclusion
GO:0031692 alpha-1B adrenergic receptor binding is a molecular function that captures the essential interaction between ligands and the alpha-1B adrenergic receptor, a key GPCR in cardiovascular and urological physiology. Structural and biophysical studies have illuminated the molecular determinants of ligand recognition and subtype selectivity, while pharmacological research continues to reveal off-target interactions and crosstalk with other receptors such as CCR1. Understanding this binding function is critical for drug discovery and for interpreting adrenergic signaling in health and disease. CRISPR-based cell models offer powerful tools to validate binding mechanisms and to explore therapeutic targeting of alpha-1B adrenergic receptor interactions.
References
- 1. Schuster M et al.. 2020. Optimizing the α(1B)-adrenergic receptor for solution NMR studies.. Biochim Biophys Acta Biomembr 1862(10):183354 PMID: 32413443
- 2. Deluigi M et al.. 2022. Crystal structure of the α(1B)-adrenergic receptor reveals molecular determinants of selective ligand recognition.. Nat Commun 13(1):382 PMID: 35046410
- 3. Civantos Calzada B et al.. 2001. Alpha-adrenoceptor subtypes.. Pharmacol Res 44(3):195-208 PMID: 11529686
- 4. Huang R et al.. 2024. Ligand-Receptor Interactions and Structure-Function Relationships in Off-Target Binding of the β(3)-Adrenergic Agonist Mirabegron to α(1A)-Adrenergic Receptors.. Int J Mol Sci 25(13) PMID: 39000575
- 5. Toyoda Y et al.. 2023. Structural basis of α(1A)-adrenergic receptor activation and recognition by an extracellular nanobody.. Nat Commun 14(1):3655 PMID: 37339967
- 6. DeSantis AJ et al.. 2021. Chemokine receptor antagonists with α(1)-adrenergic receptor blocker activity.. J Basic Clin Physiol Pharmacol 33(4):519-523 PMID: 34144642
- 7. Yuan X et al.. 2022. Site-selective covalently immobilized alpha 1A adrenergic receptor for thermodynamic and extra-thermodynamic study of four ligands binding to the receptor by chromatographic methods.. J Chromatogr A 1665:462827 PMID: 35078002
- 8. Gao X et al.. 2025. Activation of Chemokine (C-C Motif) Receptor 1 Modulates α(1B)-Adrenoceptor and Arginine Vasopressin Receptor 1A Signaling and Function.. J Am Heart Assoc 14(17):e040708 PMID: 40820981
